Imaging Acetadote Metabolism in Glioblastoma

Inclusion Criteria

• •1\. Glioblastoma
• •2\. Newly diagnosed with no prior surgery, radiation, chemotherapy, or other tumor-treating agent
• •3\. Age ≥18 years
• •4\. KPS \> 70
• •5\. Adequate organ and marrow function as defined below:
• •\- Bilirubin ≤1.5 times upper limit of normal
• •\- AST and ALT ≤ 3 times ULN
• •\- Creatinine ≤ 1.5 x ULN and/or GFR ≤ 60 mL/min
• •-ANC ≥ 1000 cells/ul
• •\- Platelet ≥ 100,000/ul
• •\- Hemoglobin ≥ 9 g/dl
• •6\. All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• •6a. A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
• •\- Has not undergone a hysterectomy or bilateral oophorectomy; or
• •\- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
• •7\. Ability to understand and the willingness to sign a written informed consent.